Project description
A novel immunotherapy for acute lymphoblastic leukaemia may be widely applicable
Interleukin 7 (IL-7) and its receptor (IL-7R) are essential for lymphoid development. Their absence leads to severe immunodeficiency. In contrast, excessive IL-7/IL-7R-mediated signalling can lead to the development of acute lymphoblastic leukaemia (ALL), and accelerate its progression and resistance to chemotherapy. Despite tremendous progress in ALL treatment, long-term remission statistics demonstrate an important need to develop more effective therapeutic strategies. IL7RsignaTHER is investigating IL-7/IL-7R-mediated signalling pathways in leukaemic cells as well as the expression of IL-7R on these cells. A better understanding of this signalling pathway could point the way to improved antibody-based biopharmaceuticals. In addition to improving ALL treatment efficacy and reducing detrimental side-effects, they may help treat many other IL-7-linked diseases and conditions.
Fields of science
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesclinical medicinegastroenterologyinflammatory bowel disease
- medical and health sciencesbasic medicineneurologymultiple sclerosis
- medical and health sciencesclinical medicineoncologycolorectal cancer
- medical and health sciencesclinical medicineoncologyleukemia
Programme(s)
Funding Scheme
ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot
Host institution
1649 028 Lisboa
Portugal
See on map
Beneficiaries (1)
1649 028 Lisboa
See on map